Reversible male subfertility due to hyperthyroidism Hyperthyroidism in women may cause oligomenorrhoea, amenorrhoea, and failure of ovulation. In men gonadal dysfunction is less apparent, though loss of libido, reduced potency,' and gynaecomastia2 may occur. We describe a man who presented with subfertility due to thyrotoxicosis and in whom normal fertility was restored with antithyroid drug treatment.
concentration was considerably raised at 68-9 nmol/l (1-9 ,tg/ml) (normal range 10-35 nmol/l; 0-2-10 ,ug/ml). Restoration of normal thyroid function with treatment with carbimazole therapy was associated with a fall in serum testosterone concentration to 20-5 mmol/l (591 mgf100 ml) and a progressive increase in sperm count. After 12 months of treatment his wife conceived and subsequently gave birth to a normal son. Response of serum thyroxine concentration, sperm count, motile sperm. and "'1 degenerate forms to treatment with carbimazole starting at month 0, Conversion: SI to traditional units-serum thyroxine: 1 mmol/l 005 ,ug/ 100 ml.
Comment
Thyrotoxic men may have reduced potency and libido,' but subfertility as a presenting complaint is extremely unusual. Oligospermia has been reported previously,'l 3 and in one subject with oligospermia testicular biopsy showed arrest of maturation at the primary spermatocyte stage.3 While there is no evidence for a direct effect of thyroid hormones on the testis in man, an indirect effect on spermatogenesis is possible through an increase in body temperature. Thyroid-stimulating immunoglobulins may affect spermatogenesis by binding to testicular receptors of thyroid-stimulating hormone. The role of these in testicular physiology is, however, not yet known.
Although the mechanism of suppression of spermatogenesis in thyrotoxicosis is unknown, changes in androgen, oestrogen, and gonadotrophin physiology have been described. One of the most striking changes is the distinct rise in serum total testosterone concentration4 5 due to an increase in sex-hormone-binding globulin.'
Free hormone concentration is, however, normal.4 Plasma oestradiol concentration is also increased in most patients,4 and there is enhanced peripheral conversion of androgen to oestrogen. Serum free oestradiol concentrations are raised and may approximate to those found in normal women in the follicular phase of the menstrual cycle.4 Gynaecomastia, which occurs especially in those with high sexhormone-binding globulin and free oestradiol concentrations,4 is detectable clinically in up to 40% of cases and by histological criteria in a higher percentage.2 Despite these changes, basal serum gonadotrophin values are normal or raised and the response to injected luteinising hormone releasing hormone is normal.' Basal serum prolactin concentration is normal, but the response to thyrotrophinreleasing hormone is diminished, returning to normal with successful treatment of the thyrotoxicosis.
Thyrotoxicosis is an unusual cause of male subfertility: this common endocrine disorder should be considered in this context for, as the present case shows, treatment may be successful in restoring normal fertility. Atenolol: side effects in a newborn infant Beta-adrenergic-blocking agents have been recommended for the management of maternal hypertension during pregnancy. Propranolol, a non-cardioselective beta-blocking agent, was used initially but later abandoned owing to the unacceptably high incidence of bradycardia, hypoglycaemia, and hypotension induced in the newborn infant.' Recently cardioselective beta-blocking agents such as oxprenolol, acebutolol, and atenolol have been advocated; though they may also produce bradycardia and hypotension in the infant at birth.2 Atenolol has a relatively long half life and needs to be administered only once daily.3 Its use during pregnancy has been incompletely documented. We report the clinical findings, together with serum and urine drug concentrations, in an infant born to a hypertensive woman treated with atenolol.
Case report
A 30-year-old multigravid woman with uncontrolled hypertension was delivered by caesarean section at 38 weeks' gestation. She weighed 64 kg and had been treated for three days with oral atenolol, 100 mg daily and phenobarbitone 30 mg eight-hourly. The infant weighed 2680 g and had one-and five-minute Apgar scores of 8 and 10 respectively with a crying pulse rate of 130 beats/minute. The maternal plasma atenolol concentration was 0-145 jLg/ml and the umbilical vein concentration 0-314 ,ug/ml.
Immediately after birth the infant appeared normal and was nursed in a closed incubator. Small milk feeds were started. Fifteen hours after delivery, however, he developed peripheral cyanosis and a prolonged capillary-filling
